Comparative Pharmacology
Head-to-head clinical analysis: FREAMINE HBC 6 9 versus FREAMINE III 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FREAMINE HBC 6 9 versus FREAMINE III 10.
FREAMINE HBC 6.9% vs FREAMINE III 10%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FREAMINE HBC 6.9% is a branched-chain amino acid (BCAA) solution that provides essential and non-essential amino acids. It promotes protein synthesis and serves as a substrate for gluconeogenesis. BCAAs may compete with tryptophan and aromatic amino acids for entry into the brain, potentially reducing hepatic encephalopathy.
FREAMINE III 10% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis and nitrogen balance in patients unable to tolerate oral or enteral nutrition.
Intravenous infusion, 1.0 to 2.0 g amino acids/kg/day (14.5 to 29.0 mL/kg/day of FREAMINE HBC 6.9%). Typically 0.5-1.0 L per day in adults, titrated to metabolic needs.
Intravenous administration as part of parenteral nutrition. Typical adult dose: 0.8-1.5 g amino acids/kg/day, infused continuously over 24 hours.
None Documented
None Documented
Not applicable as a mixture; individual amino acids have half-lives ranging from minutes to hours. For clinical purposes, infusion rate and metabolic clearance are monitored rather than half-life.
Component-dependent: free amino acids t1/2 ~15–30 min; urea cycle intermediates ca. 2 h.
Amino acids are primarily eliminated via metabolism; <2% excreted unchanged in urine. Excess nitrogen is converted to urea and excreted renally as urea. Biliary/fecal elimination is negligible.
Primarily renal; amino acids and nitrogenous waste products are excreted as urea and other metabolites. <5% fecal.
Category C
Category C
Parenteral nutrition amino acid
Parenteral nutrition amino acid